Abstract
The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including Bcl-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing
-
Animals
-
Antineoplastic Agents / pharmacology
-
Breast Neoplasms / enzymology*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Cell Cycle Proteins
-
Drug Resistance, Neoplasm*
-
ErbB Receptors / antagonists & inhibitors
-
Extracellular Matrix / drug effects
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Imidazoles / pharmacology
-
Mice
-
Ovarian Neoplasms / enzymology*
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / pathology
-
Phosphoinositide-3 Kinase Inhibitors*
-
Phosphoproteins
-
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
-
Quinolines / pharmacology
-
RNA, Messenger / metabolism
-
Receptor, IGF Type 1 / antagonists & inhibitors
-
Signal Transduction
-
Stress, Physiological
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Transplantation, Heterologous
Substances
-
Adaptor Proteins, Signal Transducing
-
Antineoplastic Agents
-
Cell Cycle Proteins
-
EIF4EBP1 protein, human
-
Imidazoles
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphoproteins
-
Proto-Oncogene Proteins c-bcl-2
-
Quinolines
-
RNA, Messenger
-
ErbB Receptors
-
Receptor, IGF Type 1
-
TOR Serine-Threonine Kinases
-
dactolisib